FrancophonIA/ELRC3.0 huggingface dataset:
English: For more information about treatment with ginkgo leaf medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravili, ki vsebujejo list ginka, preberite navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujte z zdravnikom ali farmacevtom.
English: For practical information about using ginkgo leaf medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravil z listom ginka naj bolniki preberejo navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujejo z zdravnikom ali farmacevtom.
English: Ginkgo leaf is the common name for the leaf of the plant Ginkgo biloba L. This summary covers ginkgo leaf medicines containing a specific herbal preparation made by powdering the dried leaf or as dry extract.
Slovenian: List ginka je splošno ime za list rastline Ginkgo biloba L.
English: This medicine is the same as Ariclaim, which is already authorised in the European Union (EU).
Slovenian: To zdravilo je enako zdravilu Ariclaim, ki je v Evropski uniji (EU) že pridobilo dovoljenje za promet.
English: It is available as gastroresistant capsules (blue: 20 mg; white and blue: 30 mg; orange: 40 mg; green and blue: 60 mg).
Slovenian: Na voljo je v obliki gastrorezistentnih kapsul (modre: 20 mg; bele in modre: 30 mg; oranžne: 40 mg; zelene in modre: 60 mg).
English: The benefit of treatment should be re-assessed at regular intervals.
Slovenian: Koristi zdravljenja je treba ponovno oceniti v rednih časovnih razmikih.
English: • moderate to severe stress urinary incontinence (SUI) in women.
Slovenian: • zmerne do hude stresne urinske inkontinence (SUI) pri ženskah.
English: The main measure of effectiveness was the change in the severity of pain each week, as recorded by the patients on an 11-point scale in daily diaries.
Slovenian: Glavno merilo učinkovitosti je bila sprememba jakosti bolečine vsak teden, kot so jo vsakodnevno v svojih dnevnikih zabeležili bolniki na podlagi 11-točkovne lestvice.
English: • pain due to diabetic peripheral neuropathy (damage to the nerves in the extremities that can occur in patients with diabetes).
Slovenian: • bolečin zaradi diabetične periferne nevropatije (poškodb živcev v okončinah, ki se pojavljajo pri bolnikih s sladkorno boleznijo).
English: It should not be used in patients who have certain problems with their liver or severe kidney problems.
Slovenian: Zdravilo se ne sme uporabljati pri bolnikih, ki imajo določene težave z jetri ali hude težave z ledvicami.
English: Since these neurotransmitters are also involved in reducing the sensation of pain, blocking their re-uptake into nerve cells may also improve the symptoms of neuropathic pain.
Slovenian: Ker ti živčni prenašalci sodelujejo tudi pri zmanjševanju občutka bolečine, se lahko z zaviranjem njihovega ponovnega prevzema v živčne celice izboljšajo tudi simptomi nevropatične bolečine.
English: The main measures of effectiveness were incontinence episode frequency (IEF, the number of episodes of incontinence per week) recorded in patient diaries and the patients' scores on an incontinence-specific quality-of-life (I-QOL) questionnaire.
Slovenian: Glavni merili učinkovitosti sta bili pogostnost inkontinenčnih epizod (IEF), tj. število inkontinenčnih epizod na teden, razvidno iz dnevnikov zdravljenja, ter število točk po vprašalniku o kakovosti življenja, specifičnem za inkontinenco (I-QOL).
English: It works by preventing the neurotransmitters 5-hydroxytrypamine (also called serotonin) and noradrenaline from being taken back up into nerve cells in the brain and spinal cord.
Slovenian: Deluje tako, da preprečuje ponovno prevzemanje 5hidroksitriptamina (imenovanega tudi serotonin) in noradrenalina v živčne celice možganov in hrbtenjače.
English: For diabetic neuropathic pain, the recommended dose is 60 mg once a day, but some patients may need a higher dose of 120 mg per day.
Slovenian: Pri bolnikih z bolečino diabetične nevropatije znaša priporočeni odmerek 60 mg enkrat na dan, nekateri bolniki pa bodo morda potrebovali večji odmerek v višini 120 mg na dan.
English: In both studies, pain reduction was seen from the first week of treatment for up to 12 weeks, with patients taking Duloxetine Boehringer Ingelheim having pain scores between 1.17 and 1.45 points lower than those taking placebo.
Slovenian: V obeh študijah so zmanjšanje bolečine opazili od prvega tedna zdravljenja dalje vse do 12. tedna zdravljenja, pri čemer so rezultati glede bolnikov, ki so prejemali zdravilo Duloxetine Boehringer Ingelheim, bili za 1,17 do 1,45 točke nižji od rezultatov, zabeleženih pri bolnikih, ki so jemali placebo.
English: The European Commission granted a marketing authorisation valid throughout the EU for Duloxetine Boehringer Ingelheim to Boehringer Ingelheim International GmbH on 8 October 2008.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Duloxetine Boehringer Ingelheim, veljavno po vsej Evropski uniji, odobrila družbi Boehringer Ingelheim International GmbH dne 8. oktobra 2008.
English: How duloxetine works in SUI is not clear but it is thought that by increasing the levels of 5-hydroxytryptamine and noradrenaline at the level of the nerves that control the muscle of the urethra (the tube that leads from the bladder to outside), duloxetine causes a stronger closure of the urethra during urine storage.
Slovenian: Delovanje duloksetina pri stresni urinski inkontinenci ni povsem jasno, vendar se domneva, da duloksetin s povečevanjem ravni 5-hidroksitripamina in noradrenalina v živcih, ki nadzorujejo mišice sečnice (izvodila iz sečnega mehurja navzven), okrepi stisk mišic zapiralk sečnice med shranjevanjem urina.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) DULOXETINE BOEHRINGER INGELHEIM EPAR summary for the public
Slovenian: EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) DULOXETINE BOEHRINGER INGELHEIM Povzetek EPAR za javnost
English: For the treatment of diabetic neuropathic pain, Duloxetine Boehringer Ingelheim has been studied in two 12-week studies in 809 diabetic adults who had had pain every day for at least six months.
Slovenian: Pri zdravljenju bolečine diabetične nevropatije so zdravilo Duloxetine Boehringer Ingelheim proučevali v dveh 12-tedenskih študijah pri 809 odraslih bolnikih s sladkorno boleznijo, ki so imeli vsaj šest mesecev bolečine vsak dan.
English: SUI is accidental leaks of urine during physical exertion or when coughing, laughing, sneezing, lifting or exercising;
Slovenian: Stresna urinska inkontinenca je nenadzorovano uhajanje urina med telesnim naporom, kašljanjem, smejanjem, kihanjem, dviganjem ali telesno vadbo;
English: The company that makes Ariclaim has agreed that its scientific data can be used for Duloxetine Boehringer Ingelheim.
Slovenian: Družba, ki izdeluje zdravilo Ariclaim, se je strinjala, da se lahko znanstveni podatki za to zdravilo uporabijo tudi za zdravilo Duloxetine Boehringer Ingelheim.
English: For the treatment of diabetic neuropathic pain, Duloxetine Boehringer Ingelheim at doses of 60 mg once or twice a day was more effective at reducing pain than placebo.
Slovenian: Pri zdravljenju bolečine diabetične nevropatije je bilo zdravilo Duloxetine Boehringer Ingelheim v odmerku 60 mg enkrat ali dvakrat na dan učinkovitejše pri zmanjševanju bolečine kot placebo.
English: Duloxetine Boehringer Ingelheim was more effective than placebo only in patients who had more than 14 incontinence episodes per week (moderate to severe SUI) at the start of the study.
Slovenian: Zdravilo Duloxetine Boehringer Ingelheim je bilo učinkovitejše od placeba le pri bolnicah, ki so ob začetku študije imele več kot 14 inkontinenčnih epizod na teden (zmerna do huda stresna urinska inkontinenca).
English: The effectiveness of three different doses of Duloxetine Boehringer Ingelheim was compared with that of placebo.
Slovenian: Učinkovitost treh različnih odmerkov zdravila Duloxetine Boehringer Ingelheim so primerjali z učinkovitostjo placeba.
English: In all four studies of SUI, the patients treated with Duloxetine Boehringer Ingelheim had fewer episodes of incontinence after 12 weeks, with about four or five fewer episodes of incontinence per week, in comparison with the number before the study.
Slovenian: V vseh štirih študijah zdravljenja stresne urinske inkontinence so imele bolnice, ki so prejemale zdravilo Duloxetine Boehringer Ingelheim, po 12 tednih manj inkontinenčnih epizod, in sicer približno štiri ali pet inkontinenčnih epizod manj na teden v primerjavi s številom pred študijo.
English: Duloxetine Boehringer Ingelheim can be taken with or without food.
Slovenian: Zdravilo Duloxetine Boehringer Ingelheim se lahko jemlje s hrano ali brez nje.
English: The four main studies involved 1,913 women and lasted 12 weeks, comparing Duloxetine Boehringer Ingelheim (mostly as 40 mg twice a day) with placebo (a dummy treatment).
Slovenian: V vseh štirih glavnih študijah, ki so vključevale 1 913 žensk in so trajale 12 tednov, so zdravilo Duloxetine Boehringer Ingelheim (večinoma v odmerku 40 mg dvakrat na dan) primerjali s placebom (zdravilom brez zdravilne učinkovine).
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Duloxetine Boehringer Ingelheim's benefits are greater than its risks for the treatment of moderate to severe SUI and of diabetic peripheral neuropathic pain in adults.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Duloxetine Boehringer Ingelheim pri zdravljenju zmerne do hude stresne urinske inkontinence in bolečine diabetične periferne nevropatije pri odraslih večje od z njim povezanih tveganj.
English: Duloxetine Boehringer Ingelheim must not be used together with monoamine oxidase inhibitors (a group of antidepressants), fluvoxamine (another antidepressant), or ciprofloxacin or enoxacin (types of antibiotic).
Slovenian: Zdravilo Duloxetine Boehringer Ingelheim se ne sme uporabljati sočasno z zaviralci monoaminoksidaze (skupino zdravil proti depresiji), fluvoksaminom (drugo vrsto zdravila proti depresiji) ali ciprofloksacinom ali enoksacinom (vrstama antibiotikov).
English: For the treatment of SUI, Duloxetine Boehringer Ingelheim has been studied in a total of 2,850 women.
Slovenian: Pri zdravljenju stresne urinske inkontinence so zdravilo Duloxetine Boehringer Ingelheim proučevali pri skupno 2 850 ženskah.
English: The most common side effects when used to treat diabetic neuropathic pain (seen in more than 1 patient 10) are headache, somnolence (sleepiness), dizziness, nausea and dry mouth.
Slovenian: Najpogostejši neželeni učinki pri zdravljenju bolečine diabetične nevropatije (opaženi pri več kot 1 bolniku od 10) so glavobol, somnolenca
English: The IEF decreased by 52% in the Duloxetine Boehringer Ingelheim group, compared with a decrease of 33% in the placebo-treated group.
Slovenian: Pogostnost inkontinenčnih epizod se je v skupini bolnic, ki so jemale zdravilo Duloxetine Boehringer Ingelheim, zmanjšala za 52 % v primerjavi s 33-odstotnim zmanjšanjem v skupini bolnic, ki so prejemale placebo.
English: Duloxetine Boehringer Ingelheim should not be used in people who may be hypersensitive (allergic) to duloxetine or any of the other ingredients.
Slovenian: Zdravila Duloxetine Boehringer Ingelheim ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) duloksetin ali na katero koli drugo sestavino zdravila.
English: Duloxetine Boehringer Ingelheim is a medicine that contains the active substance duloxetine.
Slovenian: Duloxetine Boehringer Ingelheim je zdravilo, ki vsebuje zdravilno učinkovino duloksetin.
English: The Committee recommended that Duloxetine Boehringer Ingelheim be given marketing authorisation.
Slovenian: Odbor je priporočil, da se za zdravilo Duloxetine Boehringer Ingelheim odobri dovoljenje za promet.
English: Duloxetine Boehringer Ingelheim must not be used in patients with certain types of liver disease or with severe kidney disease.
Slovenian: Zdravila Duloxetine Boehringer Ingelheim ne smejo uporabljati bolniki z določenimi vrstami obolenj jeter ali s hudim obolenjem ledvic.
English: By closing the urethra more powerfully, Duloxetine Boehringer Ingelheim prevents the unwanted loss of urine during physical stress such as coughing or laughing.
Slovenian: Zdravilo Duloxetine Boehringer Ingelheim s povečanjem stiska mišic zapiralk sečnice preprečuje neželeno uhajanje urina med telesnim naporom, npr. kašljanjem ali smejanjem.
English: The active substance in Duloxetine Boehringer Ingelheim, duloxetine, is a serotonin-noradrenaline re-uptake inhibitor.
Slovenian: Zdravilna učinkovina zdravila Duloxetine Boehringer Ingelheim, duloksetin, je zaviralec ponovnega prevzema serotonina in noradrenalina.
English: The most common side effects with Duloxetine Boehringer Ingelheim when used to treat SUI (seen in more than 1 patient in 10) are nausea, dry mouth, constipation and fatigue (tiredness).
Slovenian: Najpogostejši neželeni učinki zdravila Duloxetine Boehringer Ingelheim pri zdravljenju stresne urinske inkontinence (opaženi pri več kot 1 bolnici od 10) so slabost, suha usta, zaprtje in utrujenost.
English: Other information about Duloxetine Boehringer Ingelheim:
Slovenian: Druge informacije o zdravilu Duloxetine Boehringer Ingelheim:
English: For the full list of all side effects reported with Duloxetine Boehringer Ingelheim, see the Package Leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Duloxetine Boehringer Ingelheim, glejte navodilo za uporabo.
English: Duloxetine Boehringer Ingelheim is used to treat:
Slovenian: Zdravilo Duloxetine Boehringer Ingelheim se uporablja za zdravljenje:
English: What benefit has Duloxetine Boehringer Ingelheim shown during the studies?
Slovenian: Kakšne koristi je zdravilo Duloxetine Boehringer Ingelheim izkazalo med študijami?
English: The I-QOL questionnaire scores were also improved in the Duloxetine Boehringer Ingelheim group compared with the placebo group.
Slovenian: V skupini bolnic, ki so prejemale zdravilo Duloxetine Boehringer Ingelheim, se je izboljšal tudi rezultat po vprašalniku I-QOL v primerjavi s skupino, ki je prejemala placebo.
English: What is the risk associated with Duloxetine Boehringer Ingelheim?
Slovenian: Kakšna tveganja so povezana z zdravilom Duloxetine Boehringer Ingelheim?
English: The full EPAR for Duloxetine Boehringer Ingelheim is available here.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Duloxetine Boehringer Ingelheim je na voljo tukaj.
English: Why has Duloxetine Boehringer Ingelheim been approved?
Slovenian: Zakaj je bilo zdravilo Duloxetine Boehringer Ingelheim odobreno?
English: Some patients may benefit from starting treatment at a dose of 20 mg twice a day for two weeks before increasing to 40 mg twice a day, to reduce nausea (feeling sick) and dizziness.
Slovenian: Pri bolnicah s stresno urinsko inkontinenco znaša priporočeni odmerek zdravila Duloxetine Boehringer Ingelheim 40 mg dvakrat na dan. Za zmanjšanje slabosti in omotice lahko nekaterim bolnicam koristi začetno zdravljenje z odmerkom 20 mg dvakrat na dan v trajanju dveh tednov, čemur sledi zvišanje odmerka na 40 mg dvakrat na dan.
English: Duloxetine Boehringer Ingelheim should be used with caution in elderly patients.
Slovenian: Pri starejših bolnikih je zdravilo Duloxetine Boehringer Ingelheim treba uporabljati previdno.
English: What is Duloxetine Boehringer Ingelheim?
Slovenian: Kaj je zdravilo Duloxetine Boehringer Ingelheim?
English: How has Duloxetine Boehringer Ingelheim been studied?
Slovenian: Kako je bilo zdravilo Duloxetine Boehringer Ingelheim raziskano?
English: What is Duloxetine Boehringer Ingelheim used for?
Slovenian: Za kaj se zdravilo Duloxetine Boehringer Ingelheim uporablja?
English: Combining Duloxetine Boehringer Ingelheim with pelvic floor muscle training may provide additional benefit.
Slovenian: Dodatne koristi prinese kombiniranje jemanja zdravila Duloxetine Boehringer Ingelheim s programom treninga mišic medeničnega dna.
English: How is Duloxetine Boehringer Ingelheim used?
Slovenian: Kako se zdravilo Duloxetine Boehringer Ingelheim uporablja?
English: How does Duloxetine Boehringer Ingelheim work?
Slovenian: Kako zdravilo Duloxetine Boehringer Ingelheim deluje?
English: Saw palmetto fruit should only be used in male adults and the elderly.
Slovenian: Plod palmeta se sme uporabljati samo pri odraslih in starejših moških.
English: Although a possible effect in relief of lower urinary tract symptoms related to BHP was observed, there were shortcomings in the studies such as too few patients and too short a treatment period.
Slovenian: Čeprav je bil zaznan možen učinek pri lajšanju simptomov v spodnjih sečilih, povezanih z BHP, je bilo pri študijah nekaj pomanjkljivosti, na primer premalo bolnikov in prekratko obdobje zdravljenja.
English: Saw palmetto fruit is the common name for the fruit of the plant Serenoa repens (W. Bartram) Small.
Slovenian: Plod palmeta je splošno ime za plod rastline Serenoa repens (W. Bartram) Small.
English: This summary is not intended to provide practical advice on how to use medicines containing saw palmetto fruit.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o uporabi zdravil, ki vsebujejo plod palmeta.
English: If symptoms persist during the use of the medicine, a doctor or a qualified healthcare practitioner should be consulted.
Slovenian: Če simptomi med uporabo zdravila ne popustijo, se je treba posvetovati z zdravnikom ali usposobljenim zdravstvenim delavcem.
English: Herbal medicines containing saw palmetto fruit are usually available in solid forms to be taken by mouth.
Slovenian: Zdravila rastlinskega izvora, ki vsebujejo plod palmeta, so navadno na voljo v trdni obliki za jemanje skozi usta.
English: The way saw palmetto fruit acts is not fully known, but from laboratory studies it is thought to work by reducing the action of male sex hormones such as testosterone, which play a role in causing enlargement of the prostate gland in BPH; and it may also have anti-inflammatory effects.
Slovenian: Način delovanja plodu palmeta ni v celoti znan, vendar laboratorijske študije kažejo, da bi lahko zmanjševal delovanje moških spolnih hormonov, kot je testosteron, ki so vključeni v povečevanje žleze prostate pri BHP, morda pa ima tudi protivnetni učinek.
English: In its assessment, the HMPC also considered clinical studies with saw palmetto fruit ethanol extract.
Slovenian: V svoji oceni je odbor HMPC prav tako upošteval klinične študije z etanolnim ekstraktom plodu palmeta.
English: Further information on the risks associated with saw palmetto fruit medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Slovenian: Dodatne informacije o tveganjih, povezanih z zdravili, ki vsebujejo plod palmeta, vključno z ustreznimi previdnostnimi ukrepi za njihovo varno uporabo, so na voljo v monografiji na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: How does saw palmetto fruit work as a medicine?
Slovenian: Kako plod palmeta deluje kot zdravilo?
English: This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of saw palmetto fruit.
Slovenian: To je povzetek znanstvenih zaključkov Odbora za zdravila rastlinskega izvora (HMPC) v zvezi z medicinsko uporabo plodu palmeta.
English: In its assessment, the HMPC considered a number of clinical studies with saw palmetto fruit hexane extract some of which showed that it is as effective as finasteride and tamsulosin (other medicines approved to treat BPH) at treating BPH symptoms for periods up to 1 year.
Slovenian: V svoji oceni je odbor HMPC upošteval več kliničnih študij s heksanskim ekstraktom plodu palmeta, od katerih so nekatere pokazale, da je pri zdravljenju simptomov BHP v obdobju do enega leta enako učinkovit kot finasterid in tamsulozin (drugi zdravili, odobreni za zdravljenje BHP).
English: Information on the use and licensing of saw palmetto fruit medicines in EU Member States should be obtained from the relevant national authorities.
Slovenian: Za informacije o uporabi in registraciji zdravil, ki vsebujejo plod palmeta, v državah članicah EU se obrnite na pristojni nacionalni organ.
English: Any applications for the licensing of medicines containing saw palmetto fruit have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Slovenian: Vlogo za izdajo dovoljenja za promet z zdravili, ki vsebujejo plod palmeta, je treba predložiti pristojnemu nacionalnemu organu za zdravila, ki bo to vlogo za izdajo dovoljenja za promet z zdravilom rastlinskega izvora ocenil in upošteval znanstvene zaključke odbora HMPC.
English: Further information on the HMPC assessment of saw palmetto fruit medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Slovenian: Dodatne informacije o oceni zdravil, ki vsebujejo plod palmeta, ki jo je opravil odbor HMPC, vključno z njegovimi znanstvenimi zaključki, so na voljo na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: The HMPC also concluded that, on the basis of its long-standing use, saw palmetto fruit (extracted with ethanol) can be used for the relief of lower urinary tract symptoms (such as difficulty starting urination or a frequent need to urinate) related to BPH, after serious conditions have been excluded by a doctor.
Slovenian: Odbor HMPC je na podlagi dolgotrajne uporabe prav tako zaključil, da se plod palmeta (ekstrahiran z etanolom) lahko uporablja za lajšanje simptomov v spodnjih sečilih (kot so težaven začetek uriniranja in pogosto uriniranje), povezanih z BHP, potem ko zdravnik izključi hujše bolezni.
English: The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing saw palmetto fruit.
Slovenian: Ugotovitve odbora HMPC države članice EU upoštevajo pri ocenjevanju vlog za izdajo dovoljenj za promet z zdravili rastlinskega izvora, ki vsebujejo plod palmeta.
English: Saw palmetto fruit
Slovenian: Plod palmeta
English: How are saw palmetto fruit medicines approved in the EU?
Slovenian: Kako so zdravila, ki vsebujejo plod palmeta, odobrena v EU?
English: The HMPC concluded that saw palmetto fruit (extracted with hexane) can be used to treat the symptoms of benign prostatic hyperplasia (BPH).
Slovenian: Odbor HMPC je zaključil, da se plod palmeta (ekstrahiran s heksanom) lahko uporablja za zdravljenje simptomov benigne hiperplazije prostate (BHP).
English: Common side effects (seen between 1 and 10 patients in 100) reported with saw palmetto fruit are abdominal (belly) pain and headache.
Slovenian: Pri uporabi plodu palmeta so poročali o pogostih neželenih učinkih (opaženih pri 1 do 10 bolnikih od 100), in sicer o trebušnih bolečinah in glavobolu.
English: Other information about saw palmetto fruit medicines
Slovenian: Druge informacije o zdravilih, ki vsebujejo plod palmeta
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom instructions on how to take saw palmetto fruit medicines and who can use them can be found in the package leaflet that comes with the medicine.
Slovenian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
English: What evidence supports the use of saw palmetto fruit medicines?
Slovenian: Kateri dokazi podpirajo uporabo zdravil, ki vsebujejo plod palmeta?